The AstraZeneca PLC ADR AZN advanced 2.86% to $70.94 Wednesday, on what proved to be an all-around favorable trading session ...

Google's balance sheet is impressive, with negative long-term debt, $110 billion in cash, and a forward dividend yield of ...

Avitas Wealth Management LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 39.2% in the ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

For the first half of the fiscal year, analysts anticipate organic sales growth of 0.5%, net sales of $10.7bn and a 2% ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

Flagship Harbor Advisors LLC lowered its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 2.5% during the 4th ...

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo.

That’s because it’s gradually dawning on investors that they no longer can count on lower interest rates and inflation to support higher stock and bond prices. They are realizing that ...